{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"12.0","value":"8.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Analysis will be performed using Kaplan-Meier estimates. Time from date of first confirmed response of partial response or better to date of progression or death. Only patients who had a response of partial response or better will be included in this analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.\n\nMAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\ncarfilzomib: Given IV\n\ndexamethasone: Given IV or PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Carfilzomib, Dexamethasone)"}],"paramType":"MEDIAN","populationDescription":"All patients who had a response of partial response or better","reportingStatus":"POSTED","timeFrame":"Time from first evidence of PR or better to disease progression or death, assessed up to 2 years","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}